한빛사 논문
Hee-Gyeong Yia, Young Hun Jeongb, Yona Kimc, Yeong-Jin Choid,e, Hyo Eun Moonc, Sung Hye Parkf, Kyung Shin Kangg, Mihyeon Baea, Jinah Jangh,i, Hyewon Younj, Sun Ha Paekc,* & Dong-Woo Choa,*
aDepartment of Mechanical Engineering, POSTECH, Pohang, Korea
bSchool of Mechanical Engineering, Kyungpook National University, Daegu, Korea
cDepartment of Neurosurgery, Cancer Research Institute and Ischemic/Hypoxic Disease Institute, Seoul National University College of Medicine, Seoul, Korea
dDivision of Integrative Biosciences and Biotechnology, POSTECH, Pohang, Korea
ePowder & Ceramics Division, Korea Institute of Materials Science, Changwon, Korea
fDepartment of Pathology, Seoul National University College of Medicine, Seoul, Korea
gSchool of Physical Sciences and Engineering, Anderson University, Anderson, IN, USA
hDepartment of Creative IT Engineering, POSTECH, Pohang, Korea
iSchool of Interdisciplinary Bioscience and Bioengineering, POSTECH, Pohang, Korea
jDepartment of Nuclear Medicine and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
These authors contributed equally: Hee-Gyeong Yi, Young Hun Jeong.
*Correspondence to Sun Ha Paek or Dong-Woo Cho
Abstract
Patient-specific ex vivo models of human tumours that recapitulate the pathological characteristics and complex ecology of native tumours could help determine the most appropriate cancer treatment for individual patients. Here, we show that bioprinted reconstituted glioblastoma tumours consisting of patient-derived tumour cells, vascular endothelial cells and decellularized extracellular matrix from brain tissue in a compartmentalized cancer–stroma concentric-ring structure that sustains a radial oxygen gradient, recapitulate the structural, biochemical and biophysical properties of the native tumours. We also show that the glioblastoma-on-a-chip reproduces clinically observed patient-specific resistances to treatment with concurrent chemoradiation and temozolomide, and that the model can be used to determine drug combinations associated with superior tumour killing. The patient-specific tumour-on-a-chip model might be useful for the identification of effective treatments for glioblastoma patients resistant to the standard first-line treatment.
논문정보
관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
관련분야 논문보기
해당논문 저자보기